GSK & CureVac have restructured their existing partnership (they co-developed mRNA vaccines for seasonal influenza & COVID-19 in P-II and avian influenza in P-I) into a new licensing agreement
New agreement gives GSK global commercial rights & full development responsibilities of the vaccines. CureVac will get ~$430.4M upfront, ~$1.12B development, regulatory & sales milestones plus high single to low teens tiered royalties, replacing prior financials
CureVac will keep the exclusive rights of additional undisclosed infectious disease candidates from previous partnership; can develop & collaborate on mRNA vaccines for other diseases, independently. New agreement does not affect its patent litigation against Pfizer/BioNTech
Ref: GSK | Image: GSK
Related News:- CureVac collaborates with GSK to Initiate P-I/II study of Avian Influenza (H5N1)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
